Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated IMRT with Concurrent Chemotherapy for Stage III NSCLC
NCT03699033Phase 2Withdrawn
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial. Primary endpoint: Acute and late toxicities. Planned start Oct 2018; status: withdrawn.
Beyond the preview
Go deeper on NCT03699033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699033.